Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine

Generation of protective immune response against anthrax by oral immunization with protective... 1 Introduction</h5> Anthrax, a disease caused by Bacillus anthracis has gained prominence in the recent times due its potential implication as bio-warfare agent. Apart from the bioterrorist attacks, natural outbreaks continue to occur in many parts of the world especially in Central Asia, South America and Africa. The disease in nature affects animals but humans also contract the disease from animals or animal products. Recently, incidences of anthrax in wildlife from various national parks have also come in to light ( Fasanella et al., 2010; Hudson et al., 2008 ). The situation demands a pragmatic vaccination approach suitable for both human and veterinary purposes under natural circumstances or during iniquitous bioterror events.</P>The present human and veterinary anthrax vaccines rely on rather old-fashioned methods. The veterinary anthrax vaccine developed in 1930's by Sterne is essentially an attenuated, non-encapsulated, toxigenic strain of B. anthracis , while the licensed human vaccine predominantly contains ‘protective antigen’, the main immunogenic component of the tripartite anthrax toxin. Both the vaccines have potential side effects. The ancient veterinary anthrax vaccine waned in its potency and showed discrepancies in virulence leading to occasional death of animals ( Brossier et al., 1999; Shakya et al., 2007 ). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Biotechnology Elsevier

Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine

Loading next page...
 
/lp/elsevier/generation-of-protective-immune-response-against-anthrax-by-oral-xkG3Uze0zZ
Publisher
Elsevier
Copyright
Copyright © 2014 Elsevier B.V.
ISSN
0168-1656
eISSN
1873-4863
D.O.I.
10.1016/j.jbiotec.2014.01.033
Publisher site
See Article on Publisher Site

Abstract

1 Introduction</h5> Anthrax, a disease caused by Bacillus anthracis has gained prominence in the recent times due its potential implication as bio-warfare agent. Apart from the bioterrorist attacks, natural outbreaks continue to occur in many parts of the world especially in Central Asia, South America and Africa. The disease in nature affects animals but humans also contract the disease from animals or animal products. Recently, incidences of anthrax in wildlife from various national parks have also come in to light ( Fasanella et al., 2010; Hudson et al., 2008 ). The situation demands a pragmatic vaccination approach suitable for both human and veterinary purposes under natural circumstances or during iniquitous bioterror events.</P>The present human and veterinary anthrax vaccines rely on rather old-fashioned methods. The veterinary anthrax vaccine developed in 1930's by Sterne is essentially an attenuated, non-encapsulated, toxigenic strain of B. anthracis , while the licensed human vaccine predominantly contains ‘protective antigen’, the main immunogenic component of the tripartite anthrax toxin. Both the vaccines have potential side effects. The ancient veterinary anthrax vaccine waned in its potency and showed discrepancies in virulence leading to occasional death of animals ( Brossier et al., 1999; Shakya et al., 2007 ).

Journal

Journal of BiotechnologyElsevier

Published: Apr 20, 2014

References

  • Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax
    Aziz, M.A.; Singh, S.; Anand Kumar, P.; Bhatnagar, R.
  • Molecular basis for improved anthrax vaccines
    Brey, R.N.
  • Antigen delivery by attenuated Bacillus anthracis : new prospects in veterinary vaccines
    Brossier, F.; Mock, M.; Sirard, J.C.
  • Anthrax undervalued zoonosis
    Fasanella, A.; Galante, D.; Garofolo, G.; Jones, M.H.
  • Lymphokine control of in vivo immunoglobulin isotype selection
    Finkelman, F.D.; Holmes, J.; Katona, I.M.; Urban, J.F.; Beckmann, M.P.; Park, L.S.; Schooley, K.A.; Coffman, R.L.; Mosmann, T.R.; Paul, W.E.
  • Plant cell factories and mucosal vaccines
    Walmsley, A.M.; Arntzen, C.J.
  • Presentation of protective antigen to the mouse immune system: immune sequelae
    Williamson, E.D.; Beedham, R.J.; Bennett, A.M.; Perkins, S.D.; Miller, J.; Baillie, L.W.
  • Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax
    Zegers, N.D.; Kluter, E.; van der Stap, H.; van Dura, E.; van Dalen, P.; Shaw, M.; Baillie, L.
  • Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein
    Zhang, X.R.; Buehner, N.A.; Hutson, A.M.; Estes, M.K.; Mason, H.S.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off